에 대한 최신 뉴스 Jacobs Solutions (NYSE:J) 주식

JACOBS SOLUTIONS INC

Jacobs Solutions

Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $11.5 billion in revenue in fiscal 2024.

Jacobs Engineering Group

President,Donald,J.,Trump,Delivers,Remarks,During,His,Visit,To

Equities

Macro Economic Events

Global

Econ #s

Economics

Tech

AVGO

GOOGL

ORCL

UBER

AMNZ

도널드 트럼프 대통령은 화요일(13일) 사우디아라비아의 대미 6,000억 달러 투자 약속을 발표했다. 트럼프는 이를 미국-중동 경제 협력의 &#39;황금기&#39;라고 부르며 기술, 방위, 인프라 분야의 주요 미국 기업들과 수십억 달러 규모의 거래를 잇달아 열거했다.

트럼프, 사우디로부터 6천억 달러 투자 유치···&#34;시장 더 오를 것&#34; 예측

Jacobs Solutions Inc

Janus Henderson AAA CLO ETF

JAC JAPAN CO LTD ORD by Jac Japan Co., Ltd.

JAC Recruitment Co Ltd

Jack In The Box Inc

JACO ELECTRONICS INC by JACO Electronics, Inc.

Jaco Electronics Inc

Jackson Acquisition Company II Class A Ordinary Shares

Jackson Acquisition Co II

Jackson Acquisition Company II Units, each consisting of one Class A ordinary share and one right to acquire one-tenth (1/10) of one Class A ordinary share

JACCS CO by Jaccs Co.

Jackson Acquisition Company II Rights, each right to acquire one-tenth (1/10) of one Class A ordinary share

JADE ART GROUP INC by Jade Art Group, Inc.

Jade Art Group Inc

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Active Developing Markets Equity ETF

Jaguar Mining Inc

JAAG ENTERPRISES LTD. by JAAG Enterprises Ltd.

JAAG Enterprises Ltd

GREEN STREET CAPITAL CORP by Green Street Capital Corp

Green Street Capital Corp

Jaguar Health Inc

JUSTIN ALLEN HLDGS LTD by JUSTIN ALLEN HLDGS LTD.

JAPAN AIRPORT TERMINAL by Japan Airport Terminal

Japan Airport Terminal Co Ltd

JAJ DISTRIBUTION SA by JAJ DISTRIBUTION SA

Innovator Equity Defined Protection ETF - 6 Mo Jan/Jul

Jakks Pacific Inc

JAKKS PACIFIC 6% PFD A by JAKKS Pacific, Inc.

ADAMS (JOHN) LIFE CORP by Adams (JOHN) Life Corp.

John Adams Life Corp

Jamf Holding Corp

Tuktu Resources Ltd

Jammin Java Corp

Innovator ETFs Trust Premium Income 10 Barrier ETF January

Innovator ETFs Trust Innovator Premium Income 20 Barrier ETF - January

Innovator ETFs Trust Innovator Premium Income 30 Barrier ETF - January

Janel Corp

First Trust Exchange-Traded Fund VIII FT Vest U.S. Equity Max Buffer ETF - January

PGIM S&P 500 Buffer 12 ETF - January

Innovator ETFs Trust US Equity Prem Income 40 Barrier ETF - January

AllianzIM U.S. Large Cap Buffer10 Jan ETF

AIM ETF Products Trust AllianzIM U.S. Equity Buffer15 Uncapped Jan ETF

AllianzIM U.S. Large Cap Buffer20 Jan ETF

Janux Therapeutics Inc

TrueShares Structured Outcome (January) ETF

Japan Tobacco Inc

Horizon Kinetics Japan Owner Operator ETF

JAPAN SYS TECHNIQUES CO by Japan Systems Techniques Co. Ltd.

Japan System Techniques Co Ltd

JAPAN AIRLINES UNSP/ADR by Japan Airlines Ltd

Japan Airlines Co Ltd

Jupiter Acquisition Corp

Jupiter Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Jupiter Acquisition Corp Warrants (04/09/2025)

JARDINE MATHESON HLDG ORD by Jardine Matheson Holdings Ltd.

Jardine Matheson Holdings Ltd

JasmyCoin - United States Dollar

JASTEC Co Ltd

JASMINE INTL PLC NVDR by Jasmine International Public Co., Ltd.

Jasmine International PCL

JAPAN TRANSCITY CORP ORD by Japan Transcity Corp.

Japan Transcity Corp

JPMorgan Active Value ETF

Vinyl Group Ltd

PT JAYA KONSTRUKSI NEW by PT Jaya Konstruksi Manggala Pratama TBK

PT Jaya Konstruksi Manggala Pratama Tbk

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals PLC

JULIUS BAER GRUPPE NAMEN by Julius Baer Group Ltd.

Julius Baer Gruppe AG

JULIUS BAER GRP UNSP/ADR by Julius Baer Group Ltd.

Janus Detroit Street Trust Janus Henderson B-BBB CLO ETF

JBDI Holdings Ltd

JOLLIBEE FOODS CORP by Jollibee Foods Corp.

Jollibee Foods Corp

JOLLIBEE FOODS UNSP/ADR by Jollibee Foods Corp.

JBG SMITH Properties

JB HI-FI LTD UNSP/ADR by JB Hi-Fi Limited

JB Hi Fi Ltd

J.B. Hunt Transport Services, Inc. - Common Stock

JB Hunt Transport Services Inc

Janus International Group, Inc. Common Stock

Janus International Group Inc

JUMBO INTERACTIVE LTD by JUMBO INTERACTIVE LTD.

Jumbo Interactive Ltd

Jade Biosciences Inc

Lehman ABS 3.50 3.50% Adjustable Corp Backed Tr Certs GS Cap I

Jabil Inc

JetBlue Airways Corporation - Common Stock

JetBlue Airways Corp

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Active Bond ETF

SWISSCANTO ETF PREC METLS by Julius Baer Precious Metals

JACOBIO PHARMACEUTICALS by Jacobio Pharmaceuticals Group Co Ltd.

Jacobio Pharmaceuticals Group Co Ltd

JBS SA

John B. Sanfilippo & Son, Inc. - Common Stock

John B Sanfilippo & Son Inc

Jbt Bancorp Inc

JBT Marel Corp

JAMES BAY MINERALS LTD by JAMES BAY MINERALS LTD

JB&ZJMY HOLDING CO by JB&ZJMY Holding Company, Inc.

JB&ZJMY Holding Co Inc

JCDecaux SE

Nuveen Core Equity Alpha Fund Common Shares of Beneficial Interest

Nuveen Core Equity Alpha Fund

JPMORGAN CHINESE INV TR by JPMorgan Chinese Investment Trust PLC

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Active China ETF

Johnson Controls International plc Ordinary Share

Johnson Controls International PLC

JPMorgan Core Plus Bond ETF

J P MORGAN EXCHANGE-TRADED FD TR JPMorgan Inflation Managed Bond ETF

JCR PHARMACEUTICALS CO by JCR PHARMACEUTICALS CO LTD.

JCR Pharmaceuticals Co Ltd

JE Cleantech Holdings Limited - Ordinary Shares

JE Cleantech Holdings Ltd

Jewett-Cameron Trading Company - Common Shares

Jewett-Cameron Trading Co Ltd

JPMorgan Carbon Transition U.S. Equity ETF

JARDINE CYCLE&CARRAGE LTD by Jardine Cycle & Carriage Limited

Jardine Cycle & Carriage Ltd

JARDINE CYCL&CARRGE U/ADR by Jardine Cycle & Carriage Limited

JD.com, Inc. - American Depositary Shares

JD.com Inc

JUDO CAP HLDGS LTD by JUDO CAP HLDGS LTD.

Judo Capital Holdings Ltd

JD SPORTS FASHION PLC NEW by JD Sports Fashion PLC

JD Sports Fashion PLC

Wells Fargo analyst Sam Reid maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Equal-Weight and raises the price target from $65 to $73.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Masco, Raises Price Target to $73

WIIM

VUZI

VUZI stock has given up its prior gain. Vuzix shares were trading higher after the company, along with Himax Technologies, announced its AR optical module will jointly debut at Display Week 2025.

Oppenheimer analyst Jeff Jones maintains Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Outperform and lowers the price target from $21 to $20.

YMAB

Oppenheimer Maintains Outperform on Y-mAbs Therapeutics, Lowers Price Target to $20

Market Summary

General

Benzinga Market Summary: S&P Roughly Flat At Open, AMD Rises On Buyback

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) with a Overweight and lowers the price target from $20 to $16.

Wells Fargo Maintains Overweight on Metagenomi, Lowers Price Target to $16

Charles Gasparino Posts On X "Scoop: Trade-tariff deals with Japan and South Korea said to be "close," according to me Wall Street sources close to the White House. Timing unclear. India deal as well though it has been throttled by the tensions with Pakistan..."

INVZ

INVZ stock has given up its prior gain. Innoviz Technologies shares were trading higher after the company reported better-than-expected Q1 financial results and issued FY25 sales guidance with its midpoint above estimates.

Wells Fargo analyst Yanan Zhu maintains Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Overweight and lowers the price target from $50 to $45.

ARCT

Wells Fargo Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $45

Oppenheimer analyst Michael Wiederhorn maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Outperform and lowers the price target from $600 to $400.

Oppenheimer Maintains Outperform on UnitedHealth Group, Lowers Price Target to $400

ALLO

Allogene Therapeutics shares are trading lower after the company reported Q1 financial results. Also, Baird and Oppenheimer lowered their respective price targets on the stock.

Cruise line stocks are historically among the strongest seasonal performers in the S&amp;P 500 heading into the second half of May, with Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) and Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) averaging double-digit returns over a <a href="https://www.benzinga.com/topic/seasonality">three-week window.</a>
Historical data from Seasonax platforms shows that from May 14 to early June, these three stocks have consistently outperformed over the past decade, with average gains north of 10%. 
Among all S&amp;P 500 constituents, they rank at the very top for late-spring seasonality. Seasonal strength is typically fueled by ramping summer demand, strong forward bookings, and an uptick in consumer travel spending ahead of peak vacation months.
Here are the top five S&amp;P 500 stocks by average return in a three-week period starting from May 14:
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Stock</th>
<th>Avg. Return (Last 10 years)</th>
<th>Max Profit</th>
<th>Max Loss</th>
<th>Win Rate</th>
<th>Pattern Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norwegian Cruise Line</td>
<td>+13.75%</td>
<td>+149.63%</td>
<td>-6.59%</td>
<td>5/10</td>
<td>May 14 – Jun 7</td>
</tr>
<tr>
<td>Caesars Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>)</td>
<td>+11.98%</td>
<td>+102.49%</td>
<td>-0.11%</td>
<td>9/10</td>
<td>May 14 – Jun 6</td>
</tr>
<tr>
<td>Royal Caribbean</td>
<td>+11.52%</td>
<td>+113.71%</td>
<td>-7.48%</td>
<td>6/10</td>
<td>May 14 – Jun 6</td>
</tr>
<tr>
<td>Carnival Corp.</td>
<td>+11.28%</td>
<td>+103.02%</td>
<td>-5.19%</td>
<td>5/10</td>
<td>May 14 – Jun 6</td>
</tr>
<tr>
<td>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)</td>
<td>+10.69%</td>
<td>+88.13%</td>
<td>-4.95%</td>
<td>8/10</td>
<td>May 14 – Jun 7</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Seasonax</figcaption></figure>
<h3 class="wp-block-heading">RCL Sees Strong Summer Bookings</h3>
In a note from late April, Goldman Sachs analyst Lizzie Dove pointed to a strong reversal in booking momentum despite broader macro uncertainty and uneven travel data across the sector.
April bookings at RCL exceeded the same month last year, while close-in bookings remained firm. 
The company also reported stronger-than-usual onboard spending and pre-cruise purchases. Forward bookings for 2026 were tracking in line with 2024 levels but at higher prices—a sign of pricing power in an inflation-sensitive market.
With approximately 86% of the 2025 cruise calendar already booked, Dove's team raised their estimates and lifted the stock's price target from $245 to $260. However, they retained a slightly more cautious tone in 2026, pending more clarity on consumer resilience.
Since hitting tariff-driven lows on April 9, shares of RCL have surged 50% through mid-May —more than twice the gain of the S&amp;P 500. CCL shares matched the performance during the same period. 
<h3 class="wp-block-heading">NCLH Flags Demand Softness Amid Macro Pressures</h3>
In contrast, Norwegian Cruise Line is facing a different set of conditions. 
In early May, Bank of America analyst Andrew Didora highlighted NCLH as the first in the group to show softness in its 12-month forward-booked position.
While this wasn't viewed as unexpected—given the macro backdrop, consumer sentiment, and fare discounts introduced under the Oceania brand—it raised questions about forward pricing discipline across the cruise industry. Didora added that weakening demand isn't isolated to NCLH, and other operators may be seeing similar dynamics. 
BofA cut its 2025 and 2026 EPS forecasts for NCLH by 3% and 2%, now expecting $2.07 and $2.53, respectively. It revised the price objective down from $23 to $20 while maintaining a Neutral rating on concerns around leverage and top-line pressures.
Shares of NCLH have rallied 36% since April lows, underperforming versus peers. 
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45298562/chipmakers-enter-bullish-seasonal-window-5-stocks-that-could-outperform">Chipmakers Enter Bullish Seasonal Window: 5 Stocks That Could Outperform </a></li>
</ul>
Photo: Shutterstock

Travel

ENPH

NCLH

Cruises Set Sail Ahead Of Summer Boom: These 3 S&P 500 Stocks Show Strongest Late-May Seasonality

Oppenheimer analyst Jay Olson maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Outperform and lowers the price target from $15 to $13.

Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $13

Wells Fargo analyst Yanan Zhu maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Equal-Weight and lowers the price target from $1.5 to $1.

ADAP

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Lowers Price Target to $1

Wells Fargo analyst Eva Fortea Verdejo maintains ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) with a Overweight and lowers the price target from $16 to $13.

ITOS

Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $13

CREX

Creative Realities shares are trading higher. The company reported Q1 financial results.

Oppenheimer analyst Timothy Horan initiates coverage on Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Outperform rating and announces Price Target of $15.

Initiation

Core Scientific, Inc. - Class A Common Stock

CORZ

Oppenheimer Initiates Coverage On Core Scientific with Outperform Rating, Announces Price Target of $15

Wells Fargo analyst Larry Biegelsen maintains Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) with a Equal-Weight and lowers the price target from $1.29 to $0.68.

HYPR

Wells Fargo Maintains Equal-Weight on Hyperfine, Lowers Price Target to $0.68

The Tampa Bay Lightning have entered into a multi-year media rights agreement with Scripps Sports, which will make it easier than ever for fans throughout the Tampa Bay area to watch Lightning hockey games for free beginning with the start of the 2025-26 NHL season this fall.
This new agreement allows The E.W. Scripps Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) to produce and distribute all preseason, regular season and first-round playoff Lightning games that are not allocated exclusively to national broadcasts.
 &nbsp;

Tampa Bay Lightning Enters Into Multi-year Media Rights Agreement With Scripps Sports

BDSX

Biodesix shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 sales guidance below estimates.

By Javier Hasse via <a href="https://elplanteo.com/industria-cannabis-uruguay-2025/">El Planteo</a>
As debates over <a href="https://www.benzinga.com/cannabis">cannabis</a> reform continue across the globe, one country has a full decade of experience to draw from—and it just lost the man who helped make it happen.
This week, <a href="https://elplanteo.com/pepe-mujica-diario-che-guevara/">José "Pepe" Mujica</a>, the former Uruguayan president who oversaw the world's first full legalization of adult-use cannabis, <a href="https://www.benzinga.com/markets/cannabis/25/05/45392507/first-president-to-legalize-cannabis-has-died-honoring-uruguays-pepe-mujicas-legacy">passed away at the age of 89</a>. Widely revered for his humility, progressive ideals and radical honesty, Mujica's cannabis law was never about business; it was about dismantling hypocrisy and improving public health.
A decade later, the legacy of that 2013 law was front and center at C-Days 2025, a global cannabis and psychedelics summit held in Barcelona. Speaking at the event, <a href="https://elplanteo.com/industria-cannabis-uruguay-2025/">Mercedes Ponce de León</a>, founder of Latinnabis and director of Expo Cannabis Uruguay, offered a data-rich overview of Uruguay's cannabis model: its results, its limits and what it can teach the rest of the world.
<h3 class="wp-block-heading">Three Legal Channels, Over 100,000 Registered Consumers</h3>
Uruguay's adult-use system offers three legal pathways for non-medical cannabis access:
<ul class="wp-block-list">
<li>Home grow: Up to 6 flowering female plants and 480 grams per year.</li>
<li>Cannabis clubs: Non-profit associations of 15 to 45 members, with up to 99 plants and a 40-gram monthly cap per person.</li>
<li>Pharmacies: Up to 10 grams per week, sold in 5-gram packs, with four THC-limited strains authorized (up to 20% THC).</li>
</ul>
As of early 2025, 102,125 users were officially registered across these access points:
<ul class="wp-block-list">
<li>11,465 home growers</li>
<li>15,162 cannabis club members</li>
<li>75,498 pharmacy purchasers</li>
</ul>
There are also more than 460 licensed clubs and 40 pharmacies participating in the program.
<h3 class="wp-block-heading">What's Available In Pharmacies—And At What Cost?</h3>
Uruguay's state-controlled pharmacy model currently offers four cannabis strains, each with a unique THC/CBD profile and pricing structure:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Strain</th>
<th>%THC</th>
<th>%CBD</th>
<th>Psychoactivity</th>
<th>Price (UYU)</th>
<th>Approx. USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alfa</td>
<td>≤9</td>
<td>≥3</td>
<td>Medium/Low</td>
<td>$470</td>
<td>$11.24</td>
</tr>
<tr>
<td>Beta</td>
<td>≤9</td>
<td>≥3</td>
<td>Medium/Low</td>
<td>$490</td>
<td>$11.71</td>
</tr>
<tr>
<td>Gamma</td>
<td>≤15</td>
<td>≤1</td>
<td>High</td>
<td>$550</td>
<td>$13.15</td>
</tr>
<tr>
<td>Épsilon</td>
<td>≤20</td>
<td>≤1</td>
<td>High</td>
<td>$600</td>
<td>$14.34</td>
</tr>
</tbody>
</table>
</figure>
While pharmacies remain the most used access point, Mercedes Ponce de León noted that restrictions on potency, format and availability continue to limit impact and consumer satisfaction.
<h3 class="wp-block-heading">Is It Working?</h3>
Yes, though not without caveats. According to official data shared during her presentation:
<ul class="wp-block-list">
<li>Problematic cannabis use has remained stable at 2.1% since 2011.</li>
<li>Overall cannabis consumption declined from 14.6% in 2018 to 12.3% in 2024.</li>
<li>Average age of first use rose from 18 to 20 years.</li>
<li>The illicit market has shrunk significantly.</li>
</ul>
Meanwhile, Uruguay's 2024 National Drug Survey showed that 37% of cannabis users now access the plant through legal means.
<h3 class="wp-block-heading">What Still Needs Work?</h3>
Despite strong public health outcomes, the model faces several persistent challenges:
<ul class="wp-block-list">
<li>Lack of product variety and innovation</li>
<li>Uneven geographic access, with few pharmacies outside major cities</li>
<li>Logistical and financial barriers to exports</li>
<li>A broader drug policy framework that remains punitive in other areas</li>
</ul>
Ponce de León outlined four priority actions for 2025 and beyond:
<ol class="wp-block-list">
<li>Foster stronger public-private collaboration</li>
<li>Invest in research and development</li>
<li>Update regulations to expand legal access and improve user experience</li>
<li>Integrate Uruguay into global markets through ethical and sustainable trade</li>
</ol>
<h3 class="wp-block-heading">What&#8217;s Next?</h3>
Uruguay did what many countries are still debating: build a legal cannabis system that reduces harm, shrinks the illicit market and respects consumer rights. The outcomes are measurable. But so are the gaps.
In Ponce de León's words, "The positive impact is proven. But if the framework isn't updated—if access doesn't expand and innovation isn't guaranteed—the model risks becoming symbolic rather than functional."
As the world mourns the passing of Pepe Mujica, Uruguay's cannabis experiment stands as part of his lasting legacy. The road ahead will determine whether that legacy deepens—or stalls.
This article is from an external, unpaid contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.
Photo: Shutterstock

Comments

Jacobs Solutions

뉴스

에 대한 최신 뉴스 Jacobs Solutions (NYSE:J) 주식

화요일, 5월 13, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌